Table 2 Base-case results for the United States
Nivolumab | Everolimus | Incremental results | |
|---|---|---|---|
Total costs, $US | 197,089 | 163,902 | 33,186 |
Health states, $US | |||
PF | 833 | 539 | |
PD | 12,596 | 12,382 | |
Initial treatment, $US | |||
Acquisition | 138,429 | 108,859 | |
Administration | 3545 | 0 | |
Monitoring | 1011 | 655 | |
Subsequent treatment, $US | |||
Acquisition | 40,272 | 40,817 | |
Administration | 92 | 127 | |
Monitoring | 254 | 265 | |
Adverse events, $US | 56 | 257 | |
Total QALYs (discounted) | 2.79 | 2.15 | 0.64 |
PF | 0.84 | 0.54 | |
PD | 1.95 | 1.62 | |
AEs | − 0.001 | − 0.006 | |
Total LYG (discounted) | 3.36 | 2.61 | 0.74 |
Incremental cost per QALY gained, $US | 51,714 | ||
Incremental cost per LYG, $US | 44,576 |